This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

We are looking for patients who have Renal Cancer and would like to participate in a clinical trial to test a new potential treatment

Trial ID: NCT05287945

About the Trial:

We are looking for a better way to treat metastatic Renal Cell Cancer (RCC), which means cancer cells have spread from the kidneys to other parts of the body. For those with metastatic RCC, disease outcome is poor and available therapies may help relieve symptoms but not cure the disease. Orellanine, is a new potential medication, which specifically target cells in the kidney, including cancer cells. In this trial, we want to explore how safe and efficient Orellanine is at different dose levels.

This trial will include adults with metastatic renal cell cancer who have end-stage renal disease (ESRD), the advanced stage of kidney disease where kidneys could no longer function on their own. All participants should be on hemodialysis (a process wherein a machine, instead of the kidneys, cleanses the blood) for at least 3 months.

The main goal of the trial is to find the dose of Orellanine that is safe and tolerable and to learn about the effects. To take part in this trial may stop or slow your disease progression, but it’s not for sure that you will have any benefits. However, findings from this study may help other patients in the future.

Sponsor of the trial is Oncorena AB, find more information at

Estimated Enrollment

40 Participants



Who can participate?

Participants must:

  • Are at least 18 years old.
  • Have a metastatic renal cell cancer that is identified as either “clear cell renal cell cancer” (ccRCC) or “papillary renal cell cancer” (pRCC).
  • Have severe kidney disease where the kidneys can no longer function on their own. All participants must be on hemodialysis (a process where a machine, instead of the kidneys, cleans the blood) for at least 3 months.

Participants must not:

  • Have been diagnosed with any other cancer (there are exceptions to this, and trial doctors will evaluate this before they can join the trial).
  • Have cancer cells that have spread to the brain (also called “brain metastasis”)
  • Be pregnant or breastfeeding.

If you are interested in joining this trial

The trial doctor will explain what participating in the trial will mean for you. If you agree to join, the trial doctors and other site staff will perform examinations and ask you questions about your disease, your medical history, and the medications you are taking to make sure you are eligible to take part in the trial.

If you enter the trial, you will receive Orellanine as an intravenous infusion (through a needle into a vein). You will receive it once every cycle, with each cycle lasting 28 days. You will also continue with hemodialysis during the trial.

Participants will need to visit the trial site regularly during each cycle. During trial site visits, the trial doctors will:

  • Give you a physical examination and check your health
  • Collect laboratory samples like blood
  • Perform imaging tests to check your tumor status

Details about these visits and the types of tests that will be performed will be explained to you fully before you decide whether you want to join the trial.

If you wish to participate or have more information. Please e-mail : __[email protected]

The study is approved by the Swedish Ethical Review Board and the Swedish Medical Product Agency. Participation in a clinical trial is voluntary and you can leave at any time.

Frequently Asked Questions (FAQs)